Table 1.
Characteristics of Participants according to Reclassification Status by CKD-EPI eGFR Equation Compared with MDRD Study Equation
| Upward to higher eGFR category |
No reclassification |
Downward to lower eGFR category |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | N | %N | mean age |
% female |
% blacks |
% albu- minuria‡ |
%N | mean age |
% female |
% blacks |
% albu- minuria‡ |
%N | mean age |
% female |
% blacks |
% albu- minuria‡ |
|
General population
cohorts |
||||||||||||||||
| Aichi27 | 4,731 | 19% | 48 | 20% | 0% | 3% | 81% | 48 | 20% | 0% | 2% | 0% | - | - | - | - |
| ARIC*21 | 11,441 | 8% | 59 | 58% | 15% | 7% | 90% | 63 | 56% | 23% | 8% | 2% | 71 | 21% | 6% | 12% |
| AusDiab*24 | 11,179 | 25% | 45 | 60% | 0% | 4% | 74% | 54 | 54% | 0% | 7% | 1% | 77 | 27% | 0% | 23% |
| Beaver Dam CKD Study28 |
4,857 | 16% | 54 | 64% | 0% | 2% | 81% | 63 | 55% | 0.03% | 5% | 2% | 77 | 40% | 0% | 5% |
| Beijing*29 | 1,559 | 17% | 54 | 65% | 0% | 8% | 83% | 61 | 48% | 0% | 5% | 1% | 74 | 20% | 0% | 23% |
| CHS*30 | 2,988 | 0.3% | 73 | 89% | 0% | 33% | 88% | 78 | 60% | 17% | 21% | 11% | 81 | 46% | 14% | 20% |
| CIRCS31 | 11,871 | 21% | 52 | 69% | 0% | 3% | 79% | 54 | 59% | 0% | 3% | 0% | - | - | - | - |
| COBRA*32 | 2,872 | 9% | 52 | 49% | 0% | 12% | 89% | 51 | 53% | 0% | 9% | 2% | 81 | 40% | 0% | 15% |
| ESTHER33 | 9,641 | 14% | 59 | 67% | 0% | 9% | 85% | 62 | 53% | 0% | 12% | 1% | 72 | 33% | 0% | 12% |
| Framingham*34 | 2,956 | 17% | 55 | 58% | 0% | 9% | 82% | 59 | 52% | 0% | 13% | 1% | 75 | 25% | 0% | 21% |
| Gubbio*35 | 1,681 | 23% | 53 | 52% | 0% | 3% | 77% | 55 | 56% | 0% | 4% | 0% | - | - | - | - |
| HUNT*36 | 9,659 | 12% | 53 | 64% | 0% | 6% | 84% | 63 | 54% | 0% | 13% | 4% | 77 | 45% | 0% | 19% |
| IPHS37 | 95,451 | 18% | 53 | 77% | 0% | 2% | 81% | 60 | 64% | 0% | 3% | 0.3% | 76 | 12% | 0% | 4% |
| MESA*38 | 6,733 | 12% | 56 | 61% | 13% | 7% | 86% | 63 | 52% | 29% | 10% | 2% | 78 | 32% | 44% | 25% |
| MRC39 | 12,371 | 1% | 77 | 100% | 0% | 5% | 91% | 81 | 62% | 0% | 8% | 8% | 84 | 42% | 0% | 8% |
| NHANES III*40 | 15,563 | 13% | 44 | 55% | 16% | 8% | 86% | 46 | 53% | 29% | 12% | 2% | 81 | 35% | 19% | 27% |
| Ohasama41 | 1,956 | 14% | 58 | 80% | 0% | 7% | 85% | 64 | 62% | 0% | 8% | 1% | 83 | 22% | 0% | 39% |
| Okinawa8342 | 9,599 | 22% | 43 | 61% | 0% | 17% | 78% | 54 | 59% | 0% | 22% | 0.4% | 83 | 52% | 0% | 32% |
| Okinawa9343 | 93,216 | 21% | 46 | 60% | 0% | 3% | 79% | 57 | 57% | 0% | 4% | 1% | 81 | 36% | 0% | 6% |
| PREVEND*44 | 8,385 | 27% | 44 | 58% | 0.4% | 8% | 73% | 51 | 47% | 1% | 12% | 0.2% | 72 | 15% | 0% | 30% |
| RanchoBernardo*45 | 1,474 | 10% | 58 | 66% | 0% | 8% | 83% | 71 | 59% | 0.1% | 15% | 7% | 84 | 56% | 0% | 18% |
| REGARDS*46 | 27,306 | 11% | 59 | 68% | 18% | 8% | 85% | 65 | 53% | 43% | 16% | 4% | 77 | 36% | 30% | 21% |
| Severance47 | 76,201 | 29% | 42 | 53% | 0% | 5% | 71% | 47 | 48% | 0% | 5% | 0.1% | 77 | 20% | 0% | 16% |
| Taiwan48 | 515,573 | 29% | 37 | 52% | 0% | 1% | 71% | 43 | 50% | 0% | 2% | 0.1% | 80 | 22% | 0% | 9% |
| ULSAM*49 | 1,103 | 1% | 71 | 0% | 0% | 11% | 93% | 71 | 0% | 0% | 16% | 6% | 71 | 0% | 0% | 19% |
| Subtotal | 940,366 | 24% | 43 | 57% | 1% | 3% | 75% | 49 | 52% | 2% | 4% | 1% | 77 | 24% | 2% | 10% |
| High-risk cohorts | ||||||||||||||||
| ADVANCE*50 | 10595 | 10% | 62 | 57% | 0.4% | 31% | 88% | 66 | 41% | 0.3% | 31% | 2% | 74 | 25% | 1% | 26% |
| CARE51 | 4098 | 17% | 54 | 17% | 2% | 12% | 83% | 60 | 13% | 4% | 14% | 0.2% | 73 | 0% | 0% | 57% |
| KEEP52 | 77902 | 15% | 48 | 72% | 21% | 10% | 84% | 55 | 68% | 33% | 13% | 1% | 79 | 51% | 36% | 21% |
| KP Hawaii†53 | 39884 | 15% | 51 | 54% | 0% | 29% | 84% | 60 | 50% | 0% | 34% | 2% | 82 | 38% | 0% | 45% |
| MRFIT54 | 12854 | 28% | 44 | 0% | 3% | 4% | 72% | 47 | 0% | 9% | 4% | 0% | - | - | - | - |
| Pima*55 | 5066 | 4% | 46 | 68% | 0% | 37% | 96% | 32 | 56% | 0% | 19% | 0.2% | 76 | 50% | 0% | 50% |
| ZODIAC*56 | 1095 | 10% | 58 | 56% | 0% | 25% | 88% | 69 | 58% | 0% | 41% | 2% | 79 | 27% | 0% | 46% |
| Subtotal | 151,494 | 15% | 49 | 59% | 11% | 17% | 83% | 56 | 53% | 18% | 19% | 1% | 72 | 40% | 18% | 28% |
| CKD cohorts | ||||||||||||||||
| AASK†57 | 1094 | 6% | 46 | 66% | 100% | 63% | 92% | 55 | 37% | 100% | 62% | 2% | 66 | 21% | 100% | 54% |
| BC CKD*58 | 17426 | 6% | 52 | 56% | 0.1% | 76% | 90% | 70 | 45% | 0.4% | 75% | 4% | 82 | 34% | 1% | 74% |
| CRIB*59 | 308 | 3% | 49 | 38% | 0% | 63% | 95% | 62 | 34% | 6% | 87% | 2% | 77 | 17% | 17% | 100% |
| Geisinger ACR*60 | 3,361 | 3% | 59 | 63% | 3% | 50% | 96% | 71 | 54% | 2% | 43% | 1% | 79 | 6% | 0% | 56% |
| Geisinger dipstick60 | 4,509 | 3% | 57 | 80% | 6% | 32% | 96% | 72 | 62% | 1% | 25% | 2% | 81 | 27% | 3% | 27% |
| GLOMMS-1 ACR*61 | 537 | 2% | 54 | 33% | 0% | 67% | 93% | 73 | 52% | 0% | 51% | 4% | 80 | 42% | 0% | 38% |
| GLOMMS-1 PCR†61 | 470 | 4% | 41 | 47% | 0% | 88% | 91% | 70 | 48% | 0% | 95% | 5% | 83 | 43% | 0% | 100% |
| KPNW62 | 1627 | 10% | 62 | 72% | 1% | 25% | 86% | 72 | 54% | 3% | 32% | 4% | 82 | 53% | 3% | 31% |
| MASTERPLAN*63 | 636 | 11% | 49 | 47% | 3% | 78% | 88% | 62 | 29% | 3% | 86% | 1% | 72 | 50% | 0% | 75% |
| MDRD†64 | 1730 | 14% | 45 | 50% | 5% | 80% | 86% | 52 | 38% | 13% | 83% | 1% | 67 | 29% | 64% | 86% |
| MMKD†65 | 202 | 17% | 39 | 41% | 0% | 94% | 83% | 48 | 33% | 0% | 95% | 0% | - | - | - | - |
| NephroTest*66 | 928 | 9% | 48 | 33% | 8% | 51% | 89% | 61 | 31% | 10% | 65% | 2% | 75 | 0% | 13% | 73% |
| RENAAL*67 | 1513 | 9% | 55 | 34% | 8% | 100% | 90% | 61 | 37% | 15% | 100% | 1% | 68 | 0% | 67% | 100% |
| STENO*68 | 886 | 26% | 42 | 48% | 0% | 46% | 74% | 44 | 42% | 0% | 50% | 0.1% | 74 | 0% | 0% | 0% |
| Sunnybrook*69 | 3385 | 6% | 52 | 52% | 0% | 83% | 89% | 71 | 44% | 0% | 84% | 5% | 82 | 26% | 0% | 86% |
| Subtotal | 38,612 | 7% | 53 | 58% | 5% | 67% | 90% | 68 | 47% | 5% | 66% | 3% | 79 | 28% | 10% | 65% |
| Total | 1,130,472 | 23% | 44 | 57% | 3% | 7% | 77% | 51 | 52% | 5% | 8% | 1% | 77 | 26% | 4% | 15% |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
*
Studies with urine albumin-to-creatinine ratio (ACR)
†
Studies with urine protein-to-creatinine ratio (PCR)
‡
Proportion of participants with ACR ≥30 mg/g or PCR ≥50 mg/g or dipstick protein ≥1+.
The study acronyms and abbreviations are listed in online supplement p 38-39.